Back to results
US 2011/0212980 A1Published application
Combinations for the treatment of migraine
AssigneeNovartis AG
InventorsGraeme Bilbe, Baltazar Gomez-Mancilla, Daniel Hoyer, Donald Johns, Hans O. Kalkman, Kevin Hall Mcallister
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel combinations suitable for the treatment of migraine of various genesis or aetiology, which comprise, as active ingredients, at least one 5-HT1 B/1 D receptor agonist and at least one selective, competitive AMPA receptor antagonist being a 1 H-quinazoline-2,4-dione of formula (I) as defined in the claims; to their preparation; to their use as medicaments and to medicaments comprising them.
Claims19
1-17. (canceled)
A combination, which comprises:
- (A) at least one 5-HT1B/1D receptor agonist as the first active ingredient;
- and
- (B) at least one 1H-quinazoline-2,4-dione of formula (I)
- wherein
- R1 is C1-C6alkyl substituted by one, two or three substituents selected from hydroxy, C1-C6alkoxy or C5-C6cycloalkoxy;
- or
- R3 is C1-C6alkyl, hydroxy or C1-C6alkoxy-C1-C6alkyl;
- R4 is hydrogen or C1-C6alkyl;
- n is 1 or 2;
- and
- R2 is C1-C3alkyl or C1-C3fluoroalkyl;
- as the second active ingredient;
- and
- in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt.
11 more elements
Dependencies are inferred from the claim text.